Time limits apply in Florida. Find out if you still qualify.
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Verified against court and regulatory records · No upfront fees · Your information is never sold
Statute of limitations — Florida
Florida Statute § 95.11(3)(a) provides a 2-year statute of limitations for personal injury claims, including pharmaceutical product liability. The discovery rule applies — the clock begins when the plaintiff discovers or should have discovered the injury and its connection to Tepezza. Florida's 12-year statute of repose (§ 95.031(2)(b)) bars claims filed more than 12 years after the product was first delivered, but this is not yet a factor for Tepezza claims given the drug's 2020 approval.
2 years from discovery of Tepezza-related hearing injury
Filing venue
Where to File in Florida
Federal Tepezza cases from Florida are transferred to the MDL in the Northern District of Illinois (MDL No. 3079). Florida state court claims can proceed in Miami-Dade, Broward, Hillsborough, or Orange County circuit courts. Florida's tort reform amendments enacted in 2023 shortened the general personal injury statute of limitations from 4 years to 2 years, making timely filing more critical. Florida courts apply a Daubert standard for expert testimony. Florida has a significant elderly population with higher rates of thyroid conditions, contributing to a larger pool of potential Tepezza patients.
Florida data
Exposure in Florida
Florida population — third-largest in the U.S., with a disproportionately high rate of thyroid conditions due to older demographics
22.6 million
Source: U.S. Census Bureau 2024
Peak annual U.S. sales of Tepezza before the Amgen acquisition — Florida represents a major market share
$1.9 billion
Source: Horizon Therapeutics financial reports
Price Amgen paid to acquire Horizon Therapeutics in December 2023, assuming all Tepezza liabilities
$27.8 billion
Source: SEC filings
Keep reading